New 24-Valent pneumonia vaccine shows promise in kids trial
NCT ID NCT06550830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new 24-valent pneumococcal conjugate vaccine in 119 healthy children aged 2 to 17. The goal was to see if the vaccine is safe and helps the body build immunity against pneumococcal bacteria, which can cause pneumonia and other serious infections. Researchers monitored side effects for 30 days after vaccination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine aims to shield against 24 pneumonia strains
- New pneumonia vaccine trial aims to shield 3,000 kids from deadly infection
- New pneumonia vaccine shows promise in early trial for kids
- New vaccine aims to shield toddlers from 24 pneumonia strains
- New 24-Strain pneumonia vaccine trial launches for kids
- New vaccine targets 24 pneumococcal strains in major trial